BioVie (BIVI) Stock Price, News & Analysis

Company Overview

BioVie Inc. is a clinical‐stage biopharmaceutical company focused on developing novel therapies for chronic liver diseases and associated neurological complications. The company’s research and development efforts center on candidates designed to address serious unmet medical needs in hepatic encephalopathy and other liver‐related disorders. BioVie advances its pipeline through controlled clinical trials and regulatory interactions in North America.

The company’s lead product candidate, BIV201, is undergoing Phase 2 clinical evaluation for the treatment of hepatic encephalopathy, a life‐threatening condition marked by elevated neurotoxins in patients with advanced liver disease. BIV201 is being assessed for its potential to reduce ammonia levels and improve cognitive function, with data from early studies indicating a favorable safety profile and signs of clinical benefit.

In addition to its lead program, BioVie maintains exploratory efforts targeting other chronic liver indications, including primary biliary cholangitis and alcohol‐associated liver disease. These preclinical and early‐stage candidates leverage the company’s expertise in small‐molecule modulation of metabolic and inflammatory pathways, with the goal of expanding treatment options for patients who currently have limited therapeutic choices.

Headquartered in Emeryville, California, BioVie was founded with the mission of transforming the management of liver diseases through innovative drug development. The company operates in collaboration with leading academic institutions and clinical research organizations across the United States and Canada. Guided by an experienced executive team with backgrounds in biotechnology and pharmaceutical development, BioVie is committed to advancing its portfolio toward late‐stage clinical trials and eventual regulatory approval.

Key Stats

• Today's Range: $1.86 to $2.05
• 50-Day Range: $1.48 to $7.10
• 52-Week Range: $1.42 to $75.00
• Volume: 243,081 shs
• Average Volume: 126,662 shs
• Market Capitalization: $14.18 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Moderate Buy

BioVie Stock Analysis - MarketRank™

BioVie scored higher than 4% of companies evaluated by MarketBeat, and ranked 934th out of 942 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for BioVie.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of BioVie is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioVie is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

BioVie has a P/B Ratio of 0.19. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.46% of the float of BioVie has been sold short.

Short Interest Ratio / Days to Cover

BioVie has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioVie has recently increased by 3.41%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioVie does not currently pay a dividend.

Dividend Growth

BioVie does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.46% of the float of BioVie has been sold short.

Short Interest Ratio / Days to Cover

BioVie has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioVie has recently increased by 3.41%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

5 people have added BioVie to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BioVie insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.90% of the stock of BioVie is held by insiders.

Percentage Held by Institutions

Only 4.59% of the stock of BioVie is held by institutions.

BIVI Stock Analysis - Frequently Asked Questions

How have BIVI shares performed this year?

BioVie's stock was trading at $20.00 at the beginning of the year. Since then, BIVI shares have decreased by 90.4% and is now trading at $1.92.

How were BioVie's earnings last quarter?

BioVie Inc. (NASDAQ:BIVI) issued its quarterly earnings results on Monday, May, 12th. The company reported ($1.50) earnings per share for the quarter, topping the consensus estimate of ($3.20) by $1.70.

When did BioVie's stock split?

BioVie shares reverse split before market open on Monday, July 7th 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, July 6th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of BioVie?

Shares of BIVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of BioVie own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BioVie investors own include ARMOUR Residential REIT (ARR), AGNC Investment (AGNC), Hon Hai Precision Industry Co., Ltd. Sponsored GDR (HNHPF), Main Street Capital (MAIN), Ares Capital (ARCC) and PIMCO Dynamic Income Fund (PDI).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 10/06/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BIVI
• CIK: 1580149
• Web: bioviepharma.com
• Phone: (775) 888-3162
• Fax: N/A
• Employees: 10
• Year Founded: 2013

Profitability

• EPS (Trailing Twelve Months): ($79.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$17.54 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -89.02%
• Return on Assets: -75.32%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.10
• Quick Ratio: 9.10

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.93 per share
• Price / Book: 0.19

Miscellaneous

• Outstanding Shares: 7,540,000
• Free Float: 7,467,000
• Market Cap: $14.18 million
• Optionable: No Data
• Beta: 0.71